

เอกสารกำกับยาภาษาอังกฤษสำหรับแพทย์

1. Name of the Medicinal Product

1.1 Product Name

MOTILIUM® (INN: Domperidone)

MOTILIUM®-M (INN: Domperidone maleate)

1.2 Strength

Domperidone base

- White oral suspension
- The oral suspension contains 1 mg domperidone per mL.

Domperidone maleate

- Off white, round tablets (with “^{Mm} 10 ” printed on one side and the name “Janssen” appears on the other.)
- One film-coated tablet contains 12.72 mg domperidone maleate, equivalent to 10 mg domperidone.

For excipients, see *List of Excipients*.

1.3 Pharmaceutical Dosage Form

MOTILIUM: oral suspension

MOTILIUM-M: film-coated tablet

2. Qualitative and Quantitative Composition

Domperidone base

- White oral suspension
- The oral suspension contains 1 mg domperidone per mL.

Domperidone maleate

- Off white, round tablets (with “^{Mm} 10 ” printed on one side and the name “Janssen” appears on the other.)
- One film-coated tablet contains 12.72 mg domperidone maleate, equivalent to 10 mg domperidone.

For excipients, see *List of Excipients*.

3. Pharmaceutical Form

MOTILIUM: oral suspension

MOTILIUM-M: film-coated tablet

4. Clinical Particulars

4.1 Therapeutic indication

1. The dyspeptic symptom complex that is often associated with delayed gastric emptying, gastro-esophageal reflux and esophagitis:

- epigastric sense of fullness, early satiety, feeling of abdominal distension, upper abdominal pain;
 - bloating, eructation, flatulence;
 - nausea and vomiting;
 - heartburn with or without regurgitations of gastric contents in the mouth.
2. Nausea and vomiting of functional, organic, infectious or dietary origin.

For prescription use

3. Nausea and vomiting induced by:
- radiotherapy or drug therapy
 - dopamine agonists (such as L-dopa and bromocriptine) used in the treatment of Parkinson's disease.

Warnings according to the announcement from Ministry of Public Health

1. Should not use in patients with moderate to severe liver impairment.
2. Should not use in patients with existing or who have history of abnormal electrocardiogram (QT prolongation) or who administer other drugs which cause QT prolongation such as cisapride, erythromycin, ketoconazole.
3. Should not use in patients with hypokalaemia and hypomagnesaemia.
4. This drug should not be co-administered with CYP3A4 inhibitors such as ketoconazole, erythromycin, cimetidine, omeprazole as the drug plasma level will be increased.

4.2 Posology and method of administration

It is recommended to take oral MOTILIUM and MOTILIUM-M 15-30 minutes before meals. If taken after meals, absorption of the drug is somewhat delayed.

Prescription use

When MOTILIUM and MOTILIUM-M is used on prescription, the following dosing information applies:

Adults and adolescents ≥ 12 years of age and weighing ≥ 35 kg, and children <12 years of age and weighing ≥ 35 kg

The dose of MOTILIUM and MOTILIUM-M should be the lowest effective dose for the individual situation (typically 30 mg/day) and can be increased if necessary to a maximum daily oral dose of 40 mg.

Usually, the maximum treatment duration should not exceed one week for the treatment of acute nausea and vomiting. If nausea and vomiting persists for longer than one week, patients should consult their physician. For other indications, the initial duration of treatment is up to four weeks. If treatment exceeds four weeks, patients should be reevaluated and the need for continued treatment reassessed.

Formulation (domperidone per unit)	Dosage	Maximum dose per day
Film-coated tablets (10 mg/tablet)	1 tablet three to four times per day	40 mg (4×10 mg tablet).
Oral suspension (1 mg/mL)	10 mL three to four times per day	40 mg (40 mL of 1 mg/mL oral suspension)

Adults weighing < 35 kg and adolescents (≥ 12 years of age) weighing < 35 kg

The dose of MOTILIUM and MOTILIUM-M should be the lowest effective dose. The total daily dose is dependent on body weight (see table below).

Usually, the maximum treatment duration should not exceed one week for the treatment of acute nausea and vomiting. For other indications, the initial duration of treatment is up to four weeks. If treatment exceeds four weeks, patients should be reevaluated and the need for continued treatment reassessed. Film-coated tablets are unsuitable for use in adults and adolescents weighing less than 35 kg.

Formulation (domperidone per unit)	Dosage	Maximum dose per day
Oral suspension (1 mg/mL)	0.25 mg/kg three to four times per day	35 mg (1 mg/kg but no more than 35 mL)

Infants and children < 12 years of age and weighing < 35 kg

The efficacy of MOTILIUM and MOTILIUM-M has not been established in infants and children < 12 years of age and weighing < 35 kg (see *Clinical Studies*).

Non-prescription use

When MOTILIUM and MOTILIUM-M is for non-prescription use, the following dosing information applies:

Adults and adolescents 12-60 years of age and weighing ≥ 35 kg

If MOTILIUM and MOTILIUM-M is for non-prescription use:

- MOTILIUM and MOTILIUM-M can be taken as 10 mg administered up to 3 times a day to a maximum daily dose of 30 mg.
- Continuous use of MOTILIUM and MOTILIUM-M without medical consultation should not exceed 7 days for the treatment of acute nausea and vomiting and 14 days for dyspeptic symptom complex.

Adults > 60 years of age

Patients older than 60 years of age should consult their physician before taking MOTILIUM and MOTILIUM-M.

Infants and children <12 years old

MOTILIUM and MOTILIUM-M should not be administered to children <12 years old and weighing \geq 35 kg unless prescribed for use.

The efficacy of MOTILIUM and MOTILIUM-M has not been established in infants and children < 12 years of age and weighing < 35 kg (see *Clinical Studies*).

Prescription and Non-prescription use

Renal impairment

Since the elimination half-life of domperidone is prolonged in severe renal impairment (serum creatinine > 6 mg/100 mL, i.e. > 0.6 mmol/L), the dosing frequency of MOTILIUM and MOTILIUM-M should be reduced to once or twice daily, depending on the severity of the impairment, and the dose may need to be reduced. Patients with severe renal impairment should be reviewed regularly (see *Pharmacokinetic Properties*).

Hepatic impairment

MOTILIUM and MOTILIUM-M is contraindicated for patients with moderate (Child-Pugh 7 to 9) or severe (Child-Pugh >9) hepatic impairment (see *Contraindications*). Dose adjustment is not required for patients with mild (Child-Pugh 5 to 6) hepatic impairment (see *Pharmacokinetic Properties*).

4.3 Contraindication

Domperidone base and Domperidone maleate

MOTILIUM and MOTILIUM-M is contraindicated in the following situations:

- Known hypersensitivity to domperidone or any of the excipients
- Prolactin-releasing pituitary tumor (prolactinoma)
- Co-administration with potent CYP3A4 inhibitors which have been shown to cause QT interval prolongation such as, clarithromycin, erythromycin, itraconazole, oral ketoconazole, posaconazole, ritonavir, saquinavir, telithromycin, telaprevir and voriconazole (see Warnings and Precautions, Interactions)
- Whenever stimulation of gastric motility might be dangerous, e.g., in the presence of gastro-intestinal hemorrhage, mechanical obstruction or perforation
- In patients with moderate or severe hepatic impairment (see *Pharmacokinetic Properties*).

4.4 Special warning and precautions

Domperidone base and Domperidone maleate

Cardiac effects

Epidemiological studies have shown domperidone may be associated with an increased risk of serious ventricular arrhythmias or sudden cardiac death (see Adverse Reactions). Those studies suggest this increased risk may be higher in patients older than 60 years of age or in patients taking oral doses greater than 30 mg per day. Therefore, MOTILIUM and MOTILIUM-M should be used with caution in older patients.

For non-prescription use, patients older than 60 years of age should consult their physician before taking MOTILIUM and MOTILIUM-M.

Due to increased risk of ventricular arrhythmia, MOTILIUM and MOTILIUM-M is not recommended in patients with known existing prolongation of cardiac conduction intervals, particularly QTc, in patients with significant electrolyte disturbances (hypokalaemia, hyperkalaemia, hypomagnesaemia), or bradycardia, or in patients with underlying cardiac diseases such as congestive heart failure. Electrolyte disturbances (hypokalaemia, hyperkalaemia, hypomagnesaemia) and bradycardia are known to be conditions increasing the proarrhythmic risk.

Treatment with MOTILIUM and MOTILIUM-M should be stopped if signs or symptoms occur that may be associated with cardiac arrhythmia, and the patient should promptly consult their physician.

Drug interaction potential

The main metabolic pathway of domperidone is through CYP3A4. *In vitro* and human data show that the concomitant use of drugs that significantly inhibit this enzyme may result in increased plasma levels of domperidone. Co-administration of domperidone with potent CYP3A4 inhibitors which have been shown to cause QT interval prolongation is contraindicated (see *Contraindications*).

Caution should be exercised when domperidone is co-administered with potent CYP3A4 inhibitors which have not been shown to cause QT interval prolongation such as indinavir and patients should be monitored closely for signs or symptoms of adverse reactions (see *Adverse Reactions*).

Caution should be exercised when domperidone is co-administered with drugs which have been shown to cause QT interval prolongation and patients should be monitored closely for signs or symptoms of cardiovascular adverse reactions (see *Adverse Reactions*). Examples include:

- anti-arrhythmics class IA (e.g., disopyramide, quinidine)
- anti-arrhythmics class III (e.g., amiodarone, dofetilide, dronedarone, ibutilide, sotalol)
- certain antipsychotics (e.g., haloperidol, pimozide, sertindole)
- certain antidepressants (e.g., citalopram, escitalopram)

- certain antibiotics (e.g., levofloxacin, moxifloxacin)
- certain antifungal agents (e.g., pentamidine)
- certain antimalarial agents (e.g., halofantrine)
- certain gastro-intestinal drugs (e.g., dolasetron)
- certain drugs used in cancer (e.g., toremifene, vandetanib)
- certain other drugs (e.g., bepridil, methadone)

The above list is representative and not exhaustive. Please refer to relevant lists appropriate for your country.

Antacids or antisecretory agents should not be taken simultaneously with oral formulations of MOTILIUM and MOTILIUM-M as they lower the oral bioavailability of domperidone. When used concomitantly, MOTILIUM and MOTILIUM-M should be taken before meals and antacids or antisecretory agents after meals.

Excipients of MOTILIUM (domperidone base)

The oral suspension contains sorbitol and may be unsuitable for patients with sorbitol intolerance.

Excipients of MOTILIUM-M (domperidone maleate)

The film-coated tablets contain lactose and may be unsuitable for patients with lactose intolerance, galactosemia or glucose/galactose malabsorption.

4.5 Interaction with other medicinal products and other forms of interactions

The main metabolic pathway of domperidone is through CYP3A4. *In vitro* and human data show that the concomitant use of drugs that significantly inhibit this enzyme may result in increased plasma levels of domperidone.

When domperidone was co-administered with potent CYP3A4 inhibitors which have been shown to cause QT interval prolongation, clinically relevant changes in QT intervals were observed. Therefore, co-administration of domperidone with certain drugs is contraindicated (see *Contraindications*).

Caution should be exercised when domperidone is co-administered with potent CYP3A4 inhibitors which have not been shown to cause QT interval prolongation or drugs which have been shown to cause QT interval prolongation (see *Warnings and Precautions*).

Concomitant administration of anticholinergic drugs (e.g., dextromethorphan, diphenhydramine) may antagonize the anti-dyspeptic effect of MOTILIUM and MOTILIUM-M.

Theoretically, since MOTILIUM and MOTILIUM-M has gastro-kinetic effects, it could influence the absorption of concomitantly orally administered drugs, particularly those with

sustained-release or enteric-coated formulations. However, in patients already stabilized on digoxin or paracetamol, concomitant administration of domperidone did not influence the blood levels of these drugs.

MOTILIUM and MOTILIUM-M may also be given with:

- neuroleptics, the action of which it does not potentiate,
- dopaminergic agonists (bromocriptine, L-dopa), whose unwanted peripheral effects such as digestive disorders, nausea and vomiting it suppresses without counteracting their central properties.

4.6 Fertility, pregnancy and lactation

Pregnancy

There are limited post-marketing data on the use of domperidone in pregnant women. A study in rats has shown reproductive toxicity at a high, maternally toxic dose. The potential risk for humans is unknown. Therefore, MOTILIUM and MOTILIUM-M should only be used during pregnancy when justified by the anticipated therapeutic benefit.

Breast-feeding

The amount of domperidone that could be ingested by an infant through breast milk is low. The maximal relative infant dose (%) is estimated to be about 0.1% of the maternal weight-adjusted dosage. It is not known whether this is harmful to the newborn. Therefore, breast-feeding is not recommended for women who are taking MOTILIUM and MOTILIUM-M.

4.7 Effect on ability to drive and use machine

Dizziness and somnolence have been observed following use of domperidone (see *Adverse Reactions*). Therefore, patients should be advised not to drive or use machinery or engage in other activities requiring mental alertness and coordination until they have established how MOTILIUM and MOTILIUM-M affects them.

4.8 Undesirable effects

Throughout this section, adverse reactions are presented. Adverse reactions are adverse events that were considered to be reasonably associated with the use of domperidone based on the comprehensive assessment of the available adverse event information. A causal relationship with domperidone cannot be reliably established in individual cases. Further, because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Clinical Trial Data

The safety of MOTILIUM and MOTILIUM-M was evaluated in 1221 patients with gastroparesis, dyspepsia, gastro-esophageal reflux disorder (GERD), or other related conditions in 45 clinical trials included in the safety database. All patients were ≥ 15 years

old and received at least one dose of oral domperidone base. Slightly fewer than one-half (553/1221) of patients were diabetic. The median total daily dose was 80 mg (range 10 to 160 mg), with 230 patients receiving a dose greater than 80 mg. Median duration of exposure was 56 days (range 1 to 2248 days).

ARs reported by $\geq 1\%$ of patients treated with domperidone in these 45 clinical trials are shown in Table 1.

Table 1. Adverse Reactions Reported by $\geq 1\%$ of Domperidone -Treated Patients in 45 Clinical Trials

System/Organ Class	Domperidone (n=1221)
Adverse Reaction	%
Psychiatric Disorders	
Depression	2.5
Anxiety	1.6
Libido Decreased/Loss of Libido	1.5
Nervous System Disorders	
Headache	5.6
Somnolence	2.5
Akathisia	1.0
Gastrointestinal Disorders	
Diarrhea	5.2
Skin and Subcutaneous Tissue Disorders	
Rash	2.8
Pruritus	1.7
Reproductive System and Breast Disorders	
Breast Enlargement/Gynaecomastia	5.3
Breast Tenderness	4.4
Galactorrhoea	3.3
Amenorrhoea	2.9
Breast Pain	2.3
Menstruation Irregular	2.0
Lactation Disorder	1.6
General Disorders and Administration Site Conditions	
Asthenia	1.9

ARs that occurred in $< 1\%$ of Domperidone-treated patients in the 45 clinical trials (n=1221) are listed below in Table 2.

Table 2. Adverse Reactions Reported by $< 1\%$ of Domperidone -Treated Patients in 45 Clinical Trials

System/Organ Class	Domperidone(n=1221)
Adverse Reaction	%
Immune System Disorders	
Hypersensitivity	0.2
Skin and Subcutaneous Tissue Disorders	
Urticaria	0.7
Reproductive System and Breast Disorders	
Breast Discharge	0.8
Breast Swelling	0.5

The following adverse reaction has been reported with over-the-counter use: dry mouth.

Postmarketing

In addition to the ARs reported during clinical studies and listed above, the following ARs have been reported during postmarketing experience (Tables 3 and 4). In each table, the frequencies are provided according to the following convention:

Very common	$\geq 1/10$
Common	$\geq 1/100$ and $< 1/10$
Uncommon	$\geq 1/1000$ and $< 1/100$
Rare	$\geq 1/10000$ and $< 1/1000$
Very rare	$< 1/10000$, including isolated reports.

In Table 3, ARs are presented by frequency category based on spontaneous reporting rates.

Table 3. Adverse Reactions Identified During Postmarketing Experience with Domperidone by Frequency Category Estimated from Spontaneous Reporting Rates

Immune System Disorders	
<i>Very rare</i>	Anaphylactic Reaction (including Anaphylactic Shock)
Psychiatric Disorders	
<i>Very rare</i>	Agitation, Nervousness
Nervous System Disorders	
<i>Very rare</i>	Dizziness, Extrapyrarnidal Disorder, Convulsion
Cardiac Disorders	
<i>Very rare</i>	Sudden Cardiac Death*, Serious Ventricular Arrhythmias* (see <i>Warnings and Precautions</i>)
Skin and Subcutaneous Tissue Disorders	
<i>Very rare</i>	Angioedema
Renal and Urinary Disorders	
<i>Very rare</i>	Urinary Retention
Investigations	
<i>Very rare</i>	Liver Function Test Abnormal, Blood Prolactin Increased

*Based on epidemiology data

Pediatric population

In postmarketing experience, there were no differences in the safety profile of adults and children, with the exception of extrapyramidal disorder which occurred primarily in neonates and infants (up to one year of age) and other central nervous system-related effects of convulsion and agitation which were reported primarily in infants and children.

4.9 Overdose

Symptoms and signs

Overdose has been reported primarily in infants and children. Symptoms of overdose may include agitation, altered consciousness, convulsion, disorientation, somnolence and extrapyramidal reactions.

Treatment

There is no specific antidote to domperidone. Close medical supervision and supportive therapy is recommended. Anticholinergic or anti-Parkinson drugs may be helpful in controlling the extrapyramidal reactions.

It is advisable to contact a poison control center to obtain the latest recommendations for the management of an overdose.

5. Pharmacological Properties

5.1 Pharmacodynamic Properties

Pharmacotherapeutic group: Propulsives, ATC code: A03FA03

Domperidone is a dopamine antagonist with anti-emetic properties. Domperidone does not readily cross the blood-brain barrier. In domperidone users, especially in adults, extrapyramidal side effects are very rare, but domperidone promotes the release of prolactin from the pituitary. Its anti-emetic effect may be due to a combination of peripheral (gastrokinetic) effects and antagonism of dopamine receptors in the chemoreceptor trigger zone, which lies outside the blood-brain barrier in the area postrema. Animal studies, together with the low concentrations found in the brain, indicate a predominantly peripheral effect of domperidone on dopamine receptors.

Studies in man have shown oral domperidone to increase lower esophageal pressure, improve antroduodenal motility and accelerate gastric emptying. There is no effect on gastric secretion.

Effect on QT/QTc Interval and Cardiac Electrophysiology

In accordance with ICH—E14 guidelines, a thorough QT study was performed in healthy subjects. This study included a placebo, active comparator and positive control and was conducted using recommended and supra-therapeutic doses (10 and 20 mg administered 4 times a day). This study found a maximal difference of QTc between domperidone and placebo in LS-means in the change from baseline of 3.4 msec for 20 mg domperidone administered 4 times a day on Day 4, and the 2-sided 90% CI (1.0–5.9 msec) did not exceed 10 msec. The QT prolongation observed in this study when domperidone was administered according to the recommended dosing regimen is not clinically relevant.

This lack of clinical relevance is corroborated by pharmacokinetics and QTc interval data from two older studies which involved a 5-day treatment of 20 mg and 40 mg domperidone administered 4 times a day. ECGs were recorded prior to the study, on Day 5 at 1 hour (approximately at t_{max}) after the morning dose, and 3 days later. In both studies, no difference between QTc after active treatment and placebo was observed. It was therefore concluded that domperidone administration of 80 and 160 mg daily doses had no clinically significant effect on QTc in healthy subjects.

Clinical Studies

Infants and children \leq 12 years of age

A multicenter, double-blind, randomized, placebo-controlled, parallel-group, prospective study was conducted to evaluate the safety and efficacy of domperidone in 292 children with acute gastroenteritis aged 6 months to 12 years (median age 7 years). In addition to oral rehydration treatment (ORT), randomized subjects received domperidone oral suspension at 0.25 mg/kg (up to a maximum of 30 mg domperidone/day), or placebo, 3 times a day, for up to 7 days. This study did not achieve the primary objective, which was to demonstrate that domperidone suspension plus ORT is more effective than placebo plus ORT at reducing the percentage of subjects with no vomiting episodes during the first 48 hours after the first treatment administration.

5.2 Pharmacokinetic Properties

Absorption

In fasting subjects, domperidone is rapidly absorbed after oral administration, with peak plasma concentrations occurring at approximately 60 minutes after dosing. The key pharmacokinetic parameters after a single or multiple doses (administered 4 times a day) of 10 mg domperidone base tablets to healthy subjects are presented in the table below. The C_{max} and AUC values of domperidone increased proportionally with dose in the 10 mg to 20 mg dose range.

Key Domperidone Pharmacokinetic Parameters After a Single or Multiple Doses (administered 4 times a day) of 10 mg Domperidone Base Tablets to Healthy Subjects		
PK parameter	Domperidone 10 mg administered four times a day	
Mean	Day 1	Day 4
n	40	40
C_{min} , ng/mL	NA	5.26 (CV: 31.1%)
C_{max} , ng/mL	11.6 (CV: 50.8%)	17.3 (CV: 35.4%)
t_{max} , h ^a	1.02 (range: 0.52 - 5.02)	1.02 (range: 0.50 - 4.03)
AUC _{5h} , ng.h/mL	20.4 (CV: 34.4%)	47.8 (CV: 30.5%)
^a median (range)		

Source: Study DOM-DYP-1001

The low absolute bioavailability of oral domperidone (approximately 15%) is due to an extensive first-pass metabolism in the gut wall and liver. Although domperidone's bioavailability is enhanced in normal subjects when taken after a meal, patients with gastro-intestinal complaints should take domperidone 15-30 minutes before a meal. Reduced gastric acidity impairs the absorption of domperidone base. Oral bioavailability of domperidone base is decreased by prior concomitant administration of cimetidine and sodium bicarbonate. The time of peak absorption is slightly delayed and the AUC somewhat increased when the oral drug is taken after a meal.

Distribution

Domperidone is 91-93% bound to plasma proteins. Distribution studies with radiolabelled drug in animals have shown wide tissue distribution, but low brain concentration. Small amounts of drug cross the placenta in rats.

Metabolism

Domperidone undergoes rapid and extensive hepatic metabolism by hydroxylation and N-dealkylation. *In vitro* metabolism experiments with diagnostic inhibitors revealed that CYP3A4 is a major form of cytochrome P-450 involved in the N-dealkylation of domperidone, whereas CYP3A4, CYP1A2 and CYP2E1 are involved in domperidone aromatic hydroxylation.

Excretion

Urinary and fecal excretions amount to 31 and 66% of the oral dose, respectively. The proportion of the drug excreted unchanged is small (10% of fecal excretion and approximately 1% of urinary excretion).

The plasma half-life after a single oral dose is 7-9 hours in healthy subjects, but is prolonged in patients with severe renal insufficiency.

Special Populations

Hepatic impairment

In subjects with moderate hepatic impairment (Pugh score 7 to 9, Child-Pugh rating B), the AUC and C_{max} of domperidone is 2.9- and 1.5-fold higher, respectively, than in healthy subjects. The unbound fraction is increased by 25%, and the terminal elimination half-life is prolonged from 15 to 23 hours. Subjects with mild hepatic impairment have a somewhat lower systemic exposure than healthy subjects based on C_{max} and AUC, with no change in protein binding or terminal half-life. Subjects with severe hepatic impairment were not studied (see *Contraindications*).

Renal impairment

In subjects with severe renal insufficiency (serum creatinine > 6 mg/100 mL, i.e. > 0.6 mmol/L) the half-life of domperidone is increased from 7.4 to 20.8 hours, but plasma drug levels are lower than in subjects with normal renal function. Very little unchanged drug (approximately 1%) is excreted via the kidneys (see *Dosage and Administration*).

5.3 Preclinical Safety Data

At a high, maternally toxic dose of 200 mg/kg/day, teratogenic effects (organ abnormalities such as anophthalmia, microphthalmia and displacement of the subclavian artery) were seen in the rat. The clinical significance of these findings is unknown. No teratogenicity was observed in mice and rabbits.

Electrophysiological *in vitro* and *in vivo* studies have shown that domperidone, at high concentrations, may prolong the QTc interval.

In juvenile rats, a no observed adverse effect level of 10 mg/kg was observed following 30 days of once daily repeat intraperitoneal dosing. Single intraperitoneal or intravenous doses showed similar LD₅₀ values (mean range 53-76 mg/kg) in both juvenile and adult rats.

6. Pharmaceutical Particulars

6.1 List of excipients

Domperidone base

Oral suspension

Methyl-parahydroxybenzoate, microcrystalline cellulose and sodium carboxymethylcellulose, polysorbate, propyl-parahydroxybenzoate, purified water, sodium hydroxide, sodium saccharin, sorbitol liquid non-crystallising.

Domperidone maleate*Film-coated tablets*

Colloidal anhydrous silica, hypromellose, lactose monohydrate, magnesium stearate, maize starch, microcrystalline cellulose, polysorbate, polyvidone, pregelatinized potato starch, propylene glycol.

6.2 Incompatibilities

None known.

6.3 Shelf life

See expiry date on the outer pack.

6.4 Special precautions for storage

MOTILIUM: Store below 30°C.

MOTILIUM-M: Store below 30°C.

Keep out of sight and reach of children.

6.5 Nature and contents of container

- 100 ml of 1 mg/mL oral suspension with 5 ml pipette.
- Alu foil of 10 mg tablet supplied in packs with 1 x 30's and 2 x 10's

Instructions for Use and Handling

Oral suspension

Mix the contents of the bottle completely using a gentle tilting motion to avoid the formation of foam.

Directions for opening the bottle:


Fig. 1: The bottle comes with a childproof cap, and should be opened as follows:

- Push the plastic screw cap down while turning it counter-clockwise.
- Remove the unscrewed cap.

Directions for using the pipette (supplied with the 100 mL bottle only):

Fig. 2: Insert the pipette into the bottle. While holding the bottom ring, pull the top ring up to the mark corresponding to your weight in kilograms.

Fig. 3: Holding the bottom ring, remove the entire pipette from the bottle.



Empty the pipette.
Close the bottle.

Rinse the pipette with some water.

7. Marketing Authorization Holder

Janssen-Cilag Ltd.
106 Moo 4 Lad Krabang Industrial Estate,
Chalongkrung Rd., Lamplatew, Lad Krabang,
Bangkok 10520, Thailand
Tel: +662-792-7200
Fax: +662-792-7222

8. Marketing Authorization Numbers

Product Name	Marketing Authorization Number
MOTILIUM	1C XXXXX/XX
MOTILIUM-M	1C XXXXX/XX

9. Date of authorization

MOTILIUM and MOTILIUM-M CCDS for New Registration
Version 24 January 2018

created on 21 April 2020

Product Name	Date of Authorization
MOTILIUM	DDMMMYYYY
MOTILIUM-M	DDMMMYYYY

10. Date of revision of the text

24 January 2018

Manufactured by**MOTILIUM**

Janssen Pharmaceutica NV, Beerse, Belgium

MOTILIUM-M

Janssen-Cilag S.A., Val De Reuil, France

Imported by

Janssen-Cilag Ltd.

106 Moo 4 Lad Krabang Industrial Estate,
Chalongkrung Rd., Lamplatew, Lad Krabang,
Bangkok 10520, Thailand

Tel: +662-792-7200

Fax: +662-792-7222